SYRE (Spyre Therapeutics, Inc.) Stock Financials & Earnings

SYRESpyre Therapeutics, Inc.

Mkt Cap$3B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$90M

Net Income (TTM)-$155M

EPS (TTM)-$1.57

Free Cash Flow (TTM)-$169M

Gross Margin0.0%

Op. Margin-231.6%

Net Margin-171.5%

FCF Margin-187.0%

P/S Ratio (TTM)28.4x

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$198K	-$350K	-$19M
Q2 23	$688K	$688K	-$159M
Q3 23	$0	$0	-$18M
Q4 23	$0	$0	-$46M
Q1 24	$0	$0	-$48M
Q2 24	$0	$0	-$44M
Q3 24	$0	$0	-$55M
Q4 24	$0	$0	-$61M
Q1 25	$0	$0	-$54M
Q2 25	$0	$0	-$42M
Q3 25	$0	-$45M	-$57M
Q4 25	$90M	$45M	-$57M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$14M	—	$5M
Q2 23	$17M	$12M	—
Q3 23	$25M	$9M	—
Q4 23	$34M	$14M	—
Q1 24	$35M	$13M	—
Q2 24	$33M	$12M	—
Q3 24	$45M	$11M	—
Q4 24	$50M	$11M	—
Q1 25	$42M	$12M	—
Q2 25	$40M	$12M	—
Q3 25	$45M	$12M	—
Q4 25	$45M	$13M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$35M	$3M	$38M
Q2 23	$235M	$0	$235M
Q3 23	$91M	$113M	$204M
Q4 23	$189M	$150M	$339M
Q1 24	$228M	$257M	$485M
Q2 24	$45M	$381M	$426M
Q3 24	$72M	$343M	$414M
Q4 24	$89M	$514M	$603M
Q1 25	$48M	$516M	$565M
Q2 25	$82M	$445M	$527M
Q3 25	$65M	$421M	$486M
Q4 25	$86M	$671M	$757M

Shares Outstanding

Revenue Per Employee

Revenue / Employee